Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 for Injection in Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 for Injection in Subjects With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SKB 500 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Nasopharyngeal cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Sichuan Kelun Pharmaceutical Research Institute

Most Recent Events

  • 03 Jun 2026 Results presented in a Sichuan Kelun-Biotech Biopharmaceutical Media Release
  • 03 Jun 2026 According to Sichuan Kelun-Biotech Biopharmaceutical media release, Liu Haifeng is the Principal Investigator of this trial.
  • 03 Jun 2026 According to Sichuan Kelun-Biotech Biopharmaceutical media release, data from the trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top